BRCA IHC is simple, inexpensive and a potential biomarker for BRCA dysfunction in EOC patients. The sensitivity of BRCA1 IHC for detection of germline BRCA1 mutation is less than 90% of BRCA1 patients (Garg et al., 2013, Meisel et al., 2014) and less than 70% in our study.

These data suggest that BRCA1 IHC is an effective method to screen for BRCA1 alterations in patients with high-grade serous ovarian cancer. The overwhelming majority of cases with BRCA dysfunction and only a few of the BRCA unaffected cases showed loss of staining with a …

The most consistent results on IHC for BRCA1 in ovarian cancer were obtained with the anti-BRCA1 mouse monoclonal clone MS110 antibody and a cut-off of 10% of positive cells. We recommend further studies on cut-off determination based on tumour sensitivity to drugs like PARP inhibitors.

Given the potential importance of BRCA1 loss as a predictive and prognostic biomarker in high-grade serous ovarian cancer, we sought to evaluate the utility of BRCA1 immunohistochemistry (IHC) in screening for BRCA1 loss by germline, somatic, and epigenetic mechanisms.

IHC was effective to detect loss of BRCA1 protein expression in EOC; however, data on BRCA2 expression were heterogeneous and difficult to interpret.

Our goal was to assess whether immunohistochemical analysis (IHC) for BRCA1 is an effective method for the detection of BRCA1 dysfunction in molecularly characterized high-grade ovarian serous carcinoma.

Oct 10, 2009 · The IHC test has a very high sensitivity and specificity, and may substantially improve the detection of BRCA1 pathogenetic mutations in families with hereditary breast cancer. It has been suggested that the IHC analysis of ER may be a …

The immunohistochemical (IHC) detection system (Abcam, England) was used to assay the BRCA1 and BRCA2 proteins by using primary antibodies specialized for the expressed protein products of the defective (or mutated) BRCA1 and BRCA2 genes.

BRCA1 IHC interpretation was a highly reproducible and accurate modality for detecting germline, somatic, or epigenetic mechanisms of BRCA1 loss. These results support further development of BRCA1 IHC as a potential biomarker for BRCA1 loss in high-grade serous ovarian cancer.

Immunohistochemistry (IHC) using monoclonal antibodies against ER, PR, Her2/neu receptors and BRCA1 protein was performed via the fully automated immunostaining instrument ‘Ventana Benchmark’. Results: BRCA1 protein immunoexpression was detected in 20.5% of cases. It was significantly high with increasing tumour grade and stage.